Recourse Biologics is committed to advancing new and improved therapies for oncology.
Our lead molecule is RB101. RB101 is a first-in-class immunotherapeutic that increases professional killer cell persistence, memory formation, and cytotoxicity without systemic toxicity or exhaustion. RB101 is 12 months from IND.
In addition to RB101, Recourse Biologics has created an improved method of targeting and redirecting cytotoxic lymphocytes within the tumor microenvironment using our bispecific antibody platform.
Company Details
- Employees
- 5
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.recoursebio.com/
Recourse Biologics Questions
Recourse Biologics's website is http://www.recoursebio.com/
Recourse Biologics's LinkedIn profile is https://www.linkedin.com/company/recourse-biology
Recourse Biologics has
5 employees.
View email and phone details for 5
employees at Recourse Biologics.
Recourse Biologics's industry is
Biotechnology Research
Recourse Biologics's top competitors are
Kindredbio,
Bioxl Ltd,
Resonant Therapeutics,
Opera Bioscience,
Nectagen, Inc.,
Exozymes (Nasdaq: Exoz),
Courier Therapeutics,
Otolith Labs,
Monroe Biomedical Research Llc,
Morlet Family Vineyards.
Recourse Biologics's categories are Biotechnology Research
